Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | PEPD | P12955 | 2/20 | 0.43 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 8/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8169784 | 0.89 | ACE (0.48) | DPP4DPP8DPP9PEPDELANE | |
| SCHEMBL12599485 | 0.89 | CYP3A4 (0.49) | DPP4DPP8DPP9PEPDXPNPEP1 | |
| SCHEMBL8161391 | 0.88 | ELANE (0.43) | DPP4DPP8DPP9ELANECYP3A4 | |
| SCHEMBL15692923 | 0.87 | FKBP1A (0.46) | DPP4DPP8DPP9PEPDXPNPEP1 | |
| SCHEMBL8274097 | 0.84 | PEPD (0.45) | PEPDXPNPEP1POLBELANEFKBP1A | |
| SCHEMBL8168154 | 0.83 | CMA1 (0.51) | PEPDXPNPEP1ELANE | |
| SCHEMBL7316962 | 0.83 | CMA1 (0.51) | PEPDXPNPEP1ELANE | |
| SCHEMBL8352620 | 0.83 | CMA1 (0.51) | PEPDXPNPEP1ELANE | |
| SCHEMBL8169778 | 0.82 | ALDH1A1 (0.49) | DPP4DPP8DPP9PEPDXPNPEP1 | |
| SCHEMBL22209526 | 0.81 | TSHR (0.47) | DPP4DPP8DPP9PEPDXPNPEP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207528-A1 | Administering derivatives of 4-(3-pyrrolidinyloxy)quinoline | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-08-28 | — | — | US | disclosed |
| WO-2008095058-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO. LTD. (TW) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207528-A1 | Administering derivatives of 4-(3-pyrrolidinyloxy)quinoline | GLS2, SLC10A1, UGT1A1 | DPP4 456/4885DPP8 1618/4885DPP9 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.